Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP

Business Wire

a day ago

TORONTO & MONTREAL--(BUSINESS WIRE)--Genesys Capital ('Genesys') is pleased to announce the upcoming closing of Genesys Ventures IV LP ('Fund IV' or the 'fund') to continue its successful track record of building Canadian life science companies in both the medtech and biotech sectors.
"Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market."
Genesys welcomes new Limited Partners into Fund IV and thanks returning LP's that engaged early, maintained unwavering support through the fundraising process, and provided catalytic commitments of scale to the fund, in the current context of an unprecedented, ever-changing macro environment. Fund IV institutional investors include: BDC Capital, Export Development Canada (EDC), Fonds de solidarité de la Fédération des travailleurs et travailleuses du Québec (FTQ), HarbourVest, Royal Bank of Canada, Teralys Capital, Venture Ontario, and the Government of Canada's Venture Capital Catalyst Initiative (VCCI), which is administered by BDC Capital under its Life Sciences Stream. Limited Partner commitment to the Genesys franchise and the Genesys investment thesis of co-creating and investing in disruptive Canadian life science opportunities has paid off as Genesys has delivered class leading performance and increasing DPI across its successive funds.
Genesys' value-added, partnership approach to working with scientific founders provides both capital and expertise to create companies that compete on a global scale. This has anchored Genesys as a local trusted source of deal flow for global syndicate partners and a first point of contact for repeat entrepreneurs. The team at Genesys has mastered its strategy that takes advantage of the opportunity that the innovation in Canada provides.
Genesys has a distinguished history of delivering upper quartile returns across its previous funds and has stepped up into upper decile in its third fund. ​ Notable recent exits include Inversago Pharma, which was acquired by Novo Nordisk for $1.4 billion, and Fusion Pharmaceuticals, which exited to AstraZeneca for $3.3 billion. ​These successes highlight Genesys' ability to generate fund level returns driven by local Canadian innovation.
With this fund, Genesys Capital will continue to set the standard for life sciences venture capital in Canada, with a commitment to building world-class companies and delivering exceptional returns for its investors. ​
Quotes
'EDC is proud to support Genesys Capital, an important funder of companies advancing life sciences in Canada. As healthcare continues its rapid global expansion, Canada stands out with its skilled talent base, early-stage research and development capacity, and strong presence in medtech and biotech. Genesys' approach of building anchor companies will foster enduring ecosystem clusters in Canada, help drive innovation and strengthen Canada's global competitiveness in this growing sector. We look forward to seeing the transformative impact of this fund.'
Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC.
'The Fonds de solidarité FTQ's reinvestment in Genesys Capital demonstrates our confidence in a strategic player in life sciences venture capital. With its in-depth knowledge of the Quebec ecosystem and its ongoing support for emerging local companies in biotechnology, Genesys actively contributes to the sector's competitiveness and innovation.'
Maxime Pesant, Vice-President, Private Equity and Impact Investing – Life Sciences, at the Fonds de solidarité FTQ.
'Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market. It is also a strategic move to diversify the Canadian economy and ensure global competitiveness in health and biotechnology, sectors that we believe have historically delivered competitive returns for our investors.'
Senia Rapisarda, Managing Director, HarbourVest Partners.
'It is a great time to be investing out of a new fund, and we are looking forward to continuing to create best in class biopharmaceutical and medical technology companies that leverage local innovations.'
Damian Lamb, Co-founder and Managing Director, Genesys Capital.
'We are pleased to recommit to the Genesys team and vision. Ontario is recognized as a leader in the life sciences sector and home to some of the sector's most innovative start-ups. The Genesys team, headquartered in Ontario, has a unique ability to identify high-potential companies and support them in becoming global leaders. We are excited about this continued partnership.'
Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario.
'Congratulations to the Genesys team. The government's approach of co-investing alongside private VC funds through the Venture Capital Catalyst Initiative is helping boost investment in emerging sectors. Today's announcement shows that Canadian life sciences innovation is going strong and getting the support it needs to compete.'
The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions.
About Genesys
Genesys Capital is a Venture Capital Fund based in Toronto, investing in early-stage life sciences opportunities in areas of unmet medical need. With over 25 years of investment experience adhering to a consistent company creation investment strategy, Genesys has become the most successful life sciences venture firm in Canada.